Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFN1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,169
Award facts
- Contract value 100% obligated
- $28,169.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $28,169.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml syringes. DMS Pharmaceutical Group is a critical supplier within the federal pharmaceutical supply chain with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The delivery order carries an ultimate completion date of December 23, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying comprehensive pharmaceutical and medical consumable products to support Department of Defense military healthcare facilities worldwide. As one of multiple prime vendors under this broader initiative, DMS Pharmaceutical Group is positioned to fulfill diverse and specialized pharmaceutical requirements across the federal military medical system through firm fixed-price delivery orders.
Quick answers
Who was awarded contract SPE2DR26FCFN1?
SPE2DR26FCFN1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FCFN1 worth?
The government has obligated $28,169 on SPE2DR26FCFN1.
Is contract SPE2DR26FCFN1 an order under another contract?
Yes. SPE2DR26FCFN1 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFN1 competed?
The extent of competition for SPE2DR26FCFN1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award